This announcement serves to conclude agreements with pharmaceutical companies within the meaning of section 130a (8) sentence 1 SGB V. The invitation to participate is only addressed to pharmaceutical companies or groups of employees of pharmaceutical companies within the meaning of section 4 (18) of the Medicinal Products Act. It is not an open procedure according to § 15 VgV i. V. m. Section 119 (3) GWB, but to publish the invitation to conclude / join / to discount contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the discount. Contractual partners can become an unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the Medicines Act.
Clostridium botulinum toxin type A (ATC code: M03AX01)The purpose of this announcement is to conclude agreements on the active substance "Clostridium botulinum Toxin Type A (ATC code: M03AX01)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, Fifth Book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Timolol, Bimatoprost (ATC-Code: S01ED51)The purpose of this announcement is to conclude agreements on the active ingredient "timolol, bimatoprost (ATC code: S01ED51)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Trastuzumab (nur subcutaner Anwendungsbereich) (ATC-Code: L01FD01)The purpose of this announcement is to conclude agreements on the active substance "trastuzumab (only subcutaneous scope) (ATC code: L01FD01)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Perindopril, Amlodipin (ATC-Code: C09BB04)The purpose of this announcement is to conclude agreements on the active substance "perindopril, amlodipine (ATC code: C09BB04)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Sulfasalazin (ATC-Code: A07EC01) Darreichungsform: TAB, FMRThe purpose of this announcement is to conclude agreements on the active substance "sulfasalazine (ATC code: A07EC01) dosage form: TAB, FMR" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Ranibizumab (ATC-Code: S01LA04)The purpose of this announcement is to conclude agreements on the active ingredient "ranibizumab (ATC code: S01LA04)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Paliperidon palmitat (ATC-Code: N05AX13) Darreichungsform: DISThe purpose of this announcement is to conclude agreements on the active substance "Paliperidone palmitate (ATC code: N05AX13) dosage form: DIS" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Fifth Book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
lanreotide (ATC code: H01CB03)This announcement serves to conclude agreements on the active substance “lanreotide (ATC code: H01CB03)” with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 Social Code, fifth book (SGB V) (discount contracts). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the call for closing/joining discount agreements with conditions set for all participants and non-negotiable, including the amount of the discount. The corresponding information in section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical entrepreneurs or employee groups of pharmaceutical companies can become contractual partners within the meaning of Section 4 (18) of the German Medicines Act (AMG). The information in section II.2.5) is owed to the systematics of this publication form. The contract is concluded or acceded by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Adalimumab (ATC code: L04AB04)This announcement serves to conclude agreements on the active ingredient "Adalimumab (ATC code: L04AB04)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) / Accession of / to discount agreements with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form of Section 4, Paragraph 18 of the Medicines Act (AM G) will be. The information under II.2.5) is due to the systematics of this publication form. The conclusion of a contract or joining takes place by either completing the required self-declarations or evidence as well as the contract or contracts:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Imiquimod (ATC code: D06BB10)This announcement serves to conclude agreements on the active ingredient "Imiquimod (ATC code: D06BB10)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, Book V, Book V (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude / Accession of / to discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form. Contractual partners can include an unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies in the sense of of Section 4, Paragraph 18 of the Medicines Act (AMG ) become. The information under II.2.5) is due to the systematics of this publication form. The conclusion of a contract or joining takes place by either completing the required self-declarations or evidence as well as the contract or contracts:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Sunitinib (ATC-Code: L01EX01)The purpose of this announcement is to conclude agreements on the active ingredient "sunitinib (ATC code: L01EX01)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Human immunoglobulin (ATC code: J06BA02)This announcement serves to conclude agreements on the active ingredient "Human immunoglobulin (ATC code: J06BA02)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, Book Five (SGB V) (discount agreements). 130a, Paragraph 8, Clause 1 of Book V of the Social Code, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 Paragraph 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude / join discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form. There is no limit to the number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 Paragraph 18 Medicinal Mittelgesetz (AMG). The information under II.2.5) is due to the systematics of this publication form. The conclusion of a contract or joining takes place by either completing the required self-declarations or evidence as well as the contract or contracts:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Darifenacin (ATC code: G04BD10)This announcement serves to conclude agreements on the active ingredient "Darifenacin (ATC code: G04BD10)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, Book V, Book V (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) / Accession of / to discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form. Contractual partners can include an unlimited number of pharmaceutical companies or associations of pharmaceutical companies in the sense of of Section 4, Paragraph 18 of the Medicines Act (A MG). The information under II.2.5) is due to the systematics of this publication form. The conclusion of a contract or joining takes place by either completing the required self-declarations or evidence as well as the contract or contracts:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Formoterol, Aclidiniumbromid (ATC-Code: R03AL05)The purpose of this announcement is to conclude agreements on the active substance "formoterol, aclidinium bromide (ATC code: R03AL05)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Nilotinib (ATC-Code: L01EA03)The purpose of this announcement is to conclude agreements on the active ingredient "nilotinib (ATC code: L01EA03)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, fifth book (SGB V) (discount contracts). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee communities of pharmaceutical entrepreneurs within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee communities of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG) may become contractual partners. The indication under section II.2.5) is due to the scheme of this publication form. The contract is concluded or joined by the required completed self-declarations or proofs as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10.2024.
Tocilizumab (ATC code: L04AC07)This announcement serves to conclude agreements on the active ingredient "Tocilizumab (ATC code: L04AC07)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, Book V, Book V (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) / Accession of / to discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form of Section 4, Paragraph 18 of the Medicines Act (A MG). The information under II.2.5) is due to the systematics of this publication form. The conclusion of a contract or joining takes place by either completing the required self-declarations or evidence as well as the contract or contracts:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) With a qualified electronic signature (§ 126a BGB) provided with an e-mail to openhouse.rabattvertrag2022-11@kbs.de sent to the KBS.
The earliest start of the contract is 01.11.2022, provided that the contract and the required declarations or proofs have been received by KBS by 05.10.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs at KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contractual partners have been determined for the active substance(s) or combination(s) by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2024. In any case, the contracts end on 31.10,2024.